
Aim: The aim of this review article is to summarize current knowledge on the etiology, pathophysiology, diagnosis, clinical characteristics, and treatment options for cancer-related neuropathic pain (CRNP), with an emphasis on recent advances in pharmacological and non-pharmacological management strategies. Methods: A narrative review of contemporary literature and clinical recommendations on cancer-related neuropathic pain was conducted. Relevant evidence addressing the etiology, pathophysiology, diagnosis, clinical characteristics, and pharmacological and non-pharmacological management of CRNP was examined. Particular attention was given to diagnostic criteria recommended by the International Association for the Study of Pain (IASP), validated assessment tools such as the DN4 questionnaire, neuroimmune mechanisms underlying neuropathic pain, and contemporary therapeutic approaches. Results: The reviewed evidence indicates that cancer-related neuropathic pain is a complex, multifactorial condition associated with tumor invasion, nerve compression, chemotherapy- and radiotherapy-induced nerve injury, neuroinflammation, and central sensitization. Diagnosis relies on recognizing characteristic sensory symptoms and demonstrating nervous system involvement, with validated tools such as the DN4 questionnaire supporting clinical assessment. Current evidence supports multimodal pharmacological management, including opioids combined with adjuvant agents such as gabapentinoids, tricyclic antidepressants, and serotonin-norepinephrine reuptake inhibitors. Emerging approaches, including monoclonal antibodies, cannabinoids, intrathecal analgesics, and targeted molecular therapies, show promising but still limited evidence. Non-pharmacological interventions, including acupuncture, cognitive-behavioral therapies Conclusion: Cancer-related neuropathic pain remains underrecognized and difficult to treat, significantly impairing patients’ quality of life and treatment outcomes. Early diagnosis, individualized multimodal therapy, and integration of pharmacological and supportive interventions are essential for effective management. Future advances in molecular biology, immunology, and pharmacogenomics may enable more targeted and personalized therapeutic strategies for patients with cancer-related neuropathic pain.
Chronic musculoskeletal pain (CMP) is a complex clinical condition that is particularly prevalent among individuals with obesity. In addition to increased mechanical overload, its pathophysiology involves chronic low-grade systemic inflammation, adipose tissue dysfunction, metabolic abnormalities, and altered pain processing. Obesity is also associated with a higher risk of vitamin D deficiency. The aim of this narrative review was to summarize current evidence on the relationship between vitamin D deficiency, vitamin D supplementation and chronic musculoskeletal pain in overweight and obese individuals. A comprehensive literature search was conducted using the PubMed/MEDLINE and Web of Science (WoS) databases. Original research articles, systematic reviews, meta-analyses, and relevant narrative review articles were included. Current evidence suggests that vitamin D supplementation may reduce pain intensity, particularly in individuals with documented hypovitaminosis D, whereas findings in the general population remain inconsistent. Although only a limited number of studies have specifically investigated overweight and obese individuals, available randomized controlled trials suggest potential benefits of vitamin D supplementation on pain-related outcomes, especially when combined with physical activity. The underlying mechanisms are likely multifactorial and may involve vitamin D immunomodulatory and anti-inflammatory properties, improvements in musculoskeletal function and modulation of nociceptive pathways; however, these mechanisms remain incompletely understood. Current evidence does not support routine vitamin D supplementation as a sole treatment for chronic musculoskeletal pain. Nevertheless, identifying and correcting hypovitaminosis D may be a part of a multimodal treatment strategy for overweight and obese individuals.
Introduction: Epiduroscopy has emerged as a minimally invasive diagnostic and therapeutic option for chronic low back and radicular pain. This review summarises evidence from the past five years to evaluate its role in contemporary clinical practice. Methods: This review is based on selected peer-reviewed literature that addresses the mechanisms of action, diagnostic and therapeutic role, efficacy and safety of epiduroscopy in the treatment of chronic pain. Relevant literature was identified by searching PubMed and Scopus databases, published in the span of 2021.- 2026. The aim of this review is to present the contemporary use of epiduroscopy in the treatment of chronic lumbar and radicular pain with an emphasis on recent clinical studies and to summarize recent clinical findings on the use of epiduroscopy in clinical practice. Discussion: Current evidence supports epiduroscopy as an effective treatment for Persistent Spinal Pain Syndrome type 2 (PSPS type 2, formerly called Failed Back Surgery Syndrome – FBSS), lumbar spinal stenosis and radicular pain. It may also serve as a transitional therapy that may delay or reduce the need for spinal cord stimulation (SCS). In addition, epiduroscopy enables targeted delivery of therapeutic agents, including platelet-rich plasma (PRP) and corticosteroids. Although generally safe, potential complications necessitate monitoring of intracranial pressure (ICP). Conclusion: Epiduroscopy is a valuable tool in the management of chronic spinal pain and has an expanding role in clinical practice. However, the available evidence is limited by retrospective study designs and clinical heterogeneity, highlighting the need for well-designed randomised controlled trials.
Chronic pain has traditionally been defined mainly by duration. That definition explains little about why patients with similar diagnoses differ in disability and treatment response. A contemporary approach shifts focus to the underlying pain mechanism. ICD-11 supports this shift by separating chronic primary from chronic secondary pain. Management follows the same logic: rigid analgesic escalation gives way to multimodal, individualized treatment guided by function and patient goals. Personalized analgesia, including pharmacogenomics, extends this individualization further, though its role remains supportive rather than decisive. This review outlines this mechanism-based, patient-centered shift as an alternative to the traditional duration-based model.